Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.
Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology.
Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.
More about the company